| Detailed information |
|---|
| CancerLivER ID | 2059 |
| Biomarker | VEGF |
| Biomarker Name/Symbol (given in Publication) | VEGF |
| Biomolecule | Protein |
| Subject | Human |
| Degree of Validity | biomarkers indicating PLC in advanced stage and significantly associated with overall survival; but not validated on independent datasets |
| Experimental Condition | Cancer v/s Normal; predict survival of patients |
| Cancer type | Human PLC (primary liver cancer) |
| Regulation | Upregulated in at both an mRNA and protein level in patients with PLC |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 27173353 |
| Type of Biomarker | Diagnostic and Prognostic |
| Pathway | ubiquitin proteasome pathway |
| Cohort | PLC tumor tissue and blood samples were obtained from 75 patients with PLC (Primary Liver cancer) and adjacent non-tumor tissue samples. |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Human PLC (primary liver cancer) |
| Year of Publication | 2016 |
| Clinical trial | YES |
| NCT No# (Clinical trial) | NCT00055692,NCT00049322,NCT01591109,NCT00242502,NCT00471484,NCT00426829,NCT01180959,NCT00365391,NCT00410956,NCT00006198,NCT03131778,NCT03203525,NCT00949182,NCT01507740,NCT00980239,NCT00247676,NCT01502410,NCT01540435,NCT00057980,NCT00495625,NCT0101101 |